Astralis Receives Patent For the Treatment of Psoriasis and Certificate of Registration For The Brand Psoraxine From The U.S. Patent and Trademark Office.Business Editors/Health/Medical Writers FAIRFIELD, N.J.--(BUSINESS WIRE)--Jan. 15, 2004 Astralis Ltd (OTCBB OTCBB See OTC Bulletin Board (OTCBB). : ASTR ASTR American Society for Theatre Research (established in 1956) ASTR Aerospace Systems Test Reactor ASTR Aircraft Shield Test Reactor ASTR Automatic Spectral Target Recognition ASTR Army Specialized Training Reserve ) today announced that the United States Patent and Trademark Office The United States Patent and Trademark Office (PTO or USPTO) is an agency in the United States Department of Commerce that provides patent protection to inventors and businesses for their inventions, and trademark registration for product and intellectual property has issued Patent 6,673,351 Titled: Composition and Methods for the Treatment and Clinical Remission of Psoriasis to Astralis Ltd, effective on January 6, 2004. The patent focuses on Psoraxine's manufacturing and usage for the treatment and clinical remission of psoriasis, as well as a partial gene sequence of this novel protein. The patent will expire in March 2021. Astralis has already filed the patent in the European Union European Union (EU), name given since the ratification (Nov., 1993) of the Treaty of European Union, or Maastricht Treaty, to the European Community and in certain countries, including Canada, Mexico and Japan. In addition, a Certificate of Registration was awarded for the brand Psoraxine(R), Astralis' immunotherapeutic agent for the treatment of psoriasis, currently in Phase I clinical trials. Jose A. O'Daly, M.D., PhD, President of Research and Development commented, "This patent is a significant milestone in establishing Astralis' technology platform to pursue the development of future products." Notes to the Editor Astralis Ltd, a biotechnology company based in New Jersey, focuses on the research and development of novel treatments for immune system immune system Cells, cell products, organs, and structures of the body involved in the detection and destruction of foreign invaders, such as bacteria, viruses, and cancer cells. Immunity is based on the system's ability to launch a defense against such invaders. disorders and skin diseases. Psoraxine(R), administered by intramuscular injection, is a protein-based therapy that is believed to stimulate cells from the patient's immune system to reverse the inflammatory process responsible for psoriasis symptoms. Psoraxine(R) is currently being tested in U.S. Phase I clinical trials. For more information, visit Astralis' web site at www.astralisltd.com. Psoriasis Psoriasis is a chronic, genetically based remitting and relapsing scaly scal·y adj. 1. Covered or partially covered with scales. 2. Shedding scales or flakes; flaking. scaly skin condition characterized by scales; scalelike. and inflammatory skin disorder that affects approximately 3% of the world's population. Psoriasis symptoms result from the overproduction o·ver·pro·duce tr.v. o·ver·pro·duced, o·ver·pro·duc·ing, o·ver·pro·duc·es To produce in excess of need or demand. o of skin induced by blood cells blood cells, n.pl the formed elements of the blood, including red cells (erythrocytes), white cells (leukocytes), and platelets (thrombocytes). blood cells See erythrocyte and leukocyte. Platelets are classed separately. associated with the immune system. These blood cells are over-stimulated and act as though the skin was damaged, manufacturing skin cells at a much faster rate than is required by undamaged skin. The overproduction of skin can cause everything from itchy rash like patches to painful pustules and massive inflammation. Additional information can be obtained from: US National Psoriasis Foundation The National Psoriasis Foundation is a patient-driven, non-profit US-based psoriasis education and advocacy group. The National Psoriasis Foundation's mission is to improve the quality of life of the millions of Americans with psoriasis and/or psoriatic arthritis by promoting at www.psoriasis.org International Federation of Psoriasis Associations at www.ifpa-pso.org This press release may contain forward-looking statements regarding Astralis Ltd. There can be no assurance that PSORAXINE(R) will be successfully developed or manufactured, or that final results of human clinical trials will result in the regulatory approvals required to market products, or that final regulatory approval will be received in a timely manner, if at all, or that patient and physician acceptance of this product will be achieved. Astralis Ltd undertakes no obligation to revise or update any such forward-looking statement to reflect events or circumstances after the date of this release. |
|
Printer friendly
Cite/link
Email
Feedback
Reader Opinion